Read the dated pyrilutamide trial results, what changed in 2026, and what remains unknown about comparisons, combinations and safety.
Pyrilutamide has encouraging newer human trial results, but the date and design of the study matter. An earlier phase III trial did not show a statistically significant advantage over vehicle. A separate trial reported in March 2026 did. Neither result establishes that pyrilutamide is better than finasteride, minoxidil, or RU58841.
Evidence checked September 17, 2026. Pyrilutamide is also called KX-826. This guide explains what the reported results support and what remains uncertain; trial concentrations below identify study groups, not a treatment protocol.
In its 2023 annual report, Kintor described a Chinese study of 740 men with androgenetic alopecia, or pattern hair loss. Participants received a 0.5% formulation or vehicle for 24 weeks. Hair counts improved relative to baseline in the active group, but the difference from the control group was not statistically significant. Kintor annual report, page 19.
That distinction matters. A before-and-after improvement does not isolate a treatment effect when the control group also improves. The result also does not prove that every possible formulation is ineffective.
The newer phase III stage was part of a separate adaptive phase II/III program. Its results should be assessed on their own design and reporting, rather than treated as a correction to the same experiment.
Kintor's March 18 announcement describes 666 men in China, 26 research centers, 24 weeks of treatment and a further 14-day safety observation period. It reports the following changes in target-area non-vellus hair count:
| Study group | Change from baseline, hairs/cm² | Difference from vehicle, hairs/cm² |
|---|---|---|
| KX-826 1.0%, twice daily | 15.33 | 10.65 |
| KX-826 0.5%, twice daily | 14.46 | 9.78 |
| Vehicle | 4.68 | — |
Both active-versus-vehicle comparisons were reported as statistically significant. The sponsor reported no drug-related serious adverse events. These are sponsor-reported top-line findings, not an independently reproduced result or a complete safety table. March 2026 announcement.
A target-area count is a defined research measurement. It does not directly tell an individual how much their hairline will change in ordinary photographs. Nor does the numerical difference between the two active groups, by itself, establish that the higher concentration is superior: that requires the relevant comparison and its uncertainty.
The control in the newer study was vehicle, the formulation without the active ingredient. It was not finasteride, dutasteride, minoxidil, or RU58841. Comparing headline numbers from different trials can be misleading when populations, baseline hair loss, counting methods and follow-up differ.
The cited top-line announcement also cannot answer every safety question. “No drug-related serious adverse events” does not mean nobody experienced an adverse event, and a study's observation period cannot rule out every uncommon or delayed harm. A topical route alone does not establish an absence of systemic risk.
For the narrower comparison with RU58841, see our review of the human evidence for both compounds. It distinguishes trial registrations, a metabolism study and reported hair-growth findings.
Kintor's June 2026 update describes presentation of an observational study involving KX-826 and minoxidil, alongside the phase III results. An observational combination study is not the same as a randomized trial testing whether adding KX-826 improves outcomes over minoxidil alone. The announcement does not provide enough methods or numerical results to make that assessment. June conference update.
In August, the company still described a planned phase Ib/III combination trial. That is a development plan, not a completed result. Mechanistic plausibility is insufficient to recommend a drug combination, a switch from an existing treatment, or application after microneedling. August 2026 interim results, pages 4–10.
The same August report describes cosmetic sales separately from drug development. It states that a Chinese new-drug application was planned for the second half of 2026. A planned application is not an approval, and cosmetic availability does not establish an approved hair-loss indication. Those statements describe the report's date, not a guarantee about future regulatory decisions.
A bottle sold online also cannot be assumed equivalent to the formulation studied in a trial. Matching the ingredient name or advertised concentration leaves questions about formulation and manufacturing unresolved.
Before making a personal hair-loss treatment decision, take the source document to a dermatologist and identify the question that matters: replacing a treatment, adding one, adverse effects, or confirming the diagnosis. Ask which evidence actually addresses that question.
When evaluating another headline, record the population, comparator, endpoint, follow-up and reporting source. Our human-evidence checklist provides a reusable structure. If one of those details is missing, keep it marked as unknown rather than filling it with a forum claim.
This article contains no affiliate purchase links. Its original URL and publication date are retained; the update replaces unsupported switching, dosing and safety claims with dated evidence.
Powered by BTST